Drugs /

hpv16 l2/e6/e7 fusion protein vaccine ta-cin

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2\E6\E7), with potential immunoprotective and antineoplastic properties. Upon administration, HPV16 L2\E6\E7 fusion protein vaccine TA-CIN may stimulate the immune system to generate HPV16 E6\E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types.

Clinical Trials

View Clinical Trials for hpv16 l2/e6/e7 fusion protein vaccine ta-cin

Hpv16 l2/e6/e7 fusion protein vaccine ta-cin has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating hpv16 l2/e6/e7 fusion protein vaccine ta-cin, 1 is phase 1 (1 open).

CDKN2A Overexpression and HPV Positive are the most frequent biomarker inclusion criteria for hpv16 l2/e6/e7 fusion protein vaccine ta-cin clinical trials.

Cervical carcinoma is the most common disease being investigated in hpv16 l2/e6/e7 fusion protein vaccine ta-cin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Hpv16 L2/e6/e7 Fusion Protein Vaccine Ta-Cin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating hpv16 l2/e6/e7 fusion protein vaccine ta-cin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
tissue antigen-cervical intraepithelial neoplasia vaccine, tissue antigen-cervical intraepithelial neoplasia vaccine, ta-cin
NCIT ID [1]:
C121648

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.